Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. by Du Pasquier, R.A. et al.
REVIEW ARTICLE
Immunological Mechanism of Action and Clinical Profile
of Disease-Modifying Treatments in Multiple Sclerosis
Renaud A. Du Pasquier • Daniel D. Pinschewer •
Doron Merkler
Published online: 11 April 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Multiple sclerosis (MS) is a life-long, potentially
debilitating disease of the central nervous system (CNS). MS
is considered to be an immune-mediated disease, and the
presence of autoreactive peripheral lymphocytes in CNS
compartments is believed to be critical in the process of
demyelination and tissue damage in MS. Although MS is not
currently a curable disease, several disease-modifying ther-
apies (DMTs) are now available, or are in development.
These DMTs are all thought to primarily suppress autoim-
mune activity within the CNS. Each therapy has its own
mechanism of action (MoA) and, as a consequence, each has
a different efficacy and safety profile. Neurologists can now
select therapies on a more individual, patient-tailored basis,
with the aim of maximizing potential for long-term efficacy
without interruptions in treatment. The MoA and clinical
profile of MS therapies are important considerations when
making that choice or when switching therapies due to
suboptimal disease response. This article therefore reviews
the known and putative immunological MoAs alongside a
summary of the clinical profile of therapies approved for
relapsing forms of MS, and those in late-stage development,
based on published data from pivotal randomized, controlled
trials.
Key Points
Given that multiple sclerosis (MS) is a lifelong and,
as yet, incurable disease, the long-term safety and
tolerability profiles of treatments are clearly
important considerations in therapy selection.
There are now several disease-modifying therapies
(DMTs) available, or in late-stage clinical
development, for the treatment of relapsing forms of
MS in the US and the European Union (EU).
Each DMT has its own mechanisms of action and, as
a consequence, each has a different efficacy and
safety profile. Understanding the immunological
mechanisms and associated clinical profiles of each
therapy for MS is important, in order to select and
manage patients’ therapy appropriately.
Few comparative head-to-head trials have been
undertaken to assess the superiority or non-
inferiority of one therapy over another, and there is a
need for such evidence now that numerous
treatments for relapsing MS are available.
There is a need for treatment algorithms to help
physicians and their patients decide on a therapy for
optimal disease management.
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1 Introduction
Multiple sclerosis (MS) is a chronic, inflammatory dis-
ease affecting the central nervous system (CNS) [1].
While the exact cause is unknown, extensive study of the
pathology of MS has implicated autoimmune processes
in disease progression. These are thought to be mediated
by autoreactive lymphocytes that cross the blood–brain
barrier (BBB) and enter the CNS where they cause
localized inflammation resulting in demyelination, gli-
otic scarring, and axonal loss [2, 3]. According to this
model, as the disease advances, and with repeated
inflammatory episodes, CNS repair processes begin to
fail, becoming less and less effective, and neurodegen-
eration results in progressive and irreversible disability
[4].
An increased understanding of the pathophysiology of
MS has allowed the development of new immunomodu-
lating agents with unique mechanisms of action (MoA).
The most effective drugs have tended to have the most
profound effects on the immune system, which can result
in treatment-limiting adverse events [5]. Clearly, it is
important to weigh up the beneficial effects of specific
drugs against the potential adverse events so that therapies
can be prescribed in an informed manner and to the
appropriate patients.
There are several disease-modifying therapies (DMTs)
currently available, or in late-stage clinical development,
for the treatment of relapsing forms of MS in the US
and the European Union (EU). Interferon (IFN) b-1a and
b-1b and glatiramer acetate (GA) administered by
subcutaneous (SC) or intramuscular (IM) injection are
the established first-line therapies for relapsing MS
[6–15]. Natalizumab intravenous infusion has also been
approved for nearly 10 years and is used mainly as a
second-line therapy [16, 17]. Several oral drugs are also
available. In 2010, fingolimod became the first oral drug
to be approved for the treatment of relapsing forms of
MS [18, 19]. More recently, oral teriflunomide [20]
(2012) and dimethyl fumarate [21] (2013; US only)
have also been approved. Alemtuzumab, administered
as a course of infusions, was also recently approved
within the EU [22] (2013). In addition, a number of
experimental therapies are undergoing phase III clinical
trials.
This paper reviews the MoA of the approved therapies
and those in late-stage development for the treatment of
relapsing MS (Table 1). The clinical efficacy of each
therapy is also summarized, as well as the potential asso-
ciated adverse effects and safety issues.
2 Parenteral Therapies
2.1 Interferon b-1a/b
2.1.1 Mechanism of Action and Immunological Effects
Type I IFNs are endogenous cytokines produced by
eukaryotic cells in response to viral infections and related
biological stimuli. Synthetic IFNs, synthesized via recom-
binant DNA technology in mammalian cells (known as
IFNb-1a) and via bacterial fermentation (known as IFNb-
1b), are used in the treatment of relapsing MS. The bio-
logical activity of IFN is mediated via interaction with
specific cell surface receptors. Physiological and patho-
physiological effects induced by IFNs are likely to reflect
divergences in the downstream signaling induced by IFN
type I-receptor binding and resulting pleiotropic tran-
scriptional effects. As a result, the precise MoA of IFNs in
MS is not yet understood. IFNs exert direct and indirect
effects on lymphocytes, and may involve the expansion of
immunomodulatory cells such as natural killer cells and T
regulatory cells, inhibition of B-cell stimulatory capacity
and secretion [23], and inhibition of the inflammasome
[24]. IFNs also profoundly and directly influence CD8?
T-cell responses [25]. This T-cell subset predominates in
MS lesions and is associated with permanent neurological
deficits [26, 27].
It has been shown that IFNb increases the production of
anti-inflammatory cytokines and suppresses the production
of proinflammatory cytokines. In an ex vivo study, the
production of the anti-inflammatory cytokines interleukin
(IL)-10 and IL-4 were enhanced significantly in the IFNb-
treated myelin basic protein-reactive T cells, while pro-
duction of the proinflammatory cytokine, tumor necrosis
factor (TNF)a, was unaffected [28]. Such preclinical data
are supported by those from clinical studies. For example,
in blood and cerebrospinal fluid (CSF) samples collected
from patients with MS who were receiving treatment with
IFNb-1a, serum and CSF IL-10 levels increased with
increasing treatment exposure [29]. Further studies showed
that administration of IFNb down-regulates expression of
the proinflammatory cytokines IL-17 and osteopontin [30],
and reduced serum IFNc and TNFa in patients with MS,
while increasing production of IL-10 [31].
The pharmacological actions of IFNb described above
have been attributed to its direct action on CD4? T cells
[30] and myeloid cells [32] through the type I IFN receptor,
although IFNb signaling with other cell types within the
immune system is also thought to contribute to its thera-
peutic effects [33]. IFNb is likely to have a limited direct
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effect on the CNS. The brain is relatively isolated from the
immune system by the BBB, and it has not been estab-
lished what doses of IFN would be needed to achieve
physiologically relevant concentrations in CSF. It is pos-
sible that IFNs cross the BBB at sites of CNS inflamma-
tion. Alternatively, and not mutually exclusively, CNS
effects of IFNs may be related to inhibition of inflamma-
tory cell migration across the BBB [34].
2.1.2 Clinical Effects in Relapsing MS
Injectable IFNs have been the mainstay of MS treatment
for around 20 years, and are frequently used as first-line
therapy. Table 2 summarizes data regarding clinical effi-
cacy (effect on disease relapses and disability progression)
of the IFNb formulations from randomized, placebo-con-
trolled, phase III trials. The clinical efficacy in comparative
randomized trials is summarized in Table 3. Meta-analyses
show that IFNb is associated with a significant effect on
MS relapses and disability progression compared with
placebo [38, 39]; however, the effect of IFNb therapy on
disability progression has been disputed, as a large-scale,
retrospective study of prospectively collected data dem-
onstrated that IFNb was not associated with a reduction in
disability progression [35–37]. A consideration relating to
the efficacy of the IFNb formulations is the potential for
Table 1 Mechanisms of action of approved and phase III disease-modifying therapies for multiple sclerosis
Therapy Summary First
approved
Interferon b-1a/b Increases production of anti-inflammatory cytokines and suppresses production of proinflammatory
cytokines [28, 30, 31]
1993
Reduces inflammatory cell migration across the blood–brain barrier [175]
Glatiramer acetate Is a synthetic peptide with amino acid analogs to myelin basic protein 1996
Increases production of anti-inflammatory cytokines and decreases production of proinflammatory
cytokines [23]
Mitoxantrone Cytotoxic agent that intercalates with DNA, causing strand breaks, and inhibits DNA repair via inhibition of
topoisomerase II [55]
2000a
Inhibits proliferation of B and T lymphocytes and macrophages [54]
Natalizumab Is a monoclonal antibody, which selectively inhibits VLA-4 (a4b1) integrins and prevents lymphocyte
migration across the blood–brain barrier [59]
2004
Fingolimod Is a sphingosine 1-phosphate receptor modulator that reversibly redistributes lymphocytes into lymphoid
tissue, whilst preserving lymphocyte function [98]
2010
Prevents naı¨ve and central memory T cells from circulating to non-lymphoid tissues, including those of the
CNS, where they could cause inflammatory tissue damage [98, 101]
Teriflunomide Is an active metabolite of leflunomide 2012
Inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis,
which has a cytostatic effect on proliferating T and B cells [124]
Dimethyl fumarate
(BG-12)
Dimethyl fumarate is a methyl ester of fumaric acid 2013
Thought to exert neuroprotective action in addition to anti-inflammatory effects, via the activation of the
Nrf-2 pathway [138, 139]
Alemtuzumab Is a monoclonal antibody that targets CD52, a cell surface protein predominantly found in B and T
lymphocytes [89]
2013b
Depletes lymphocyte populations and leads to a distinctive pattern of lymphocyte repopulation [90]
Laquinimod Is thought to work by increasing production of anti-inflammatory cytokines and decreasing production of
proinflammatory cytokines [23, 154]
–
May also reduce leukocyte migration into the CNS [153, 155]
Daclizumab Is a humanized monoclonal antibody which binds to the a-subunit (CD25) of the IL-2 receptor expressed on
activated T cells and regulatory T cells [156]
–
Inhibits several IL-2-dependent T-cell functions, including antigen- and mitogen-induced proliferation and
cytokine secretion by activated Th1 and Th2 lymphocytes [157]
Ocrelizumab Is a humanized, recombinant monoclonal antibody reactive against CD20, which is widely expressed on B
cells [162]
–
Depletes B cells [163]
CNS central nervous system, IL interleukin, Nrf-2 nuclear factor (erythroid-derived 2)-like 2, Th T helper, VLA very late antigen
a Mitoxantrone was approved for use in the US only in 2000
b Alemtuzumab received marketing authorization in the EU only in 2013
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patients to produce neutralizing antibodies. Although the
role of neutralizing antibodies is not fully understood, it is
thought that they lead to treatment resistance and can
therefore reduce treatment efficacy over the long term [38,
39].
All three forms of IFNb are generally well tolerated.
The most common adverse events are flu-like symptoms,
headaches, and injection site reactions, as summarized in
Table 4. However, due to the effect of IFNb on circulating
lymphocyte numbers, formulations are also associated with
mild lymphopenia.
More recently, a formulation of IFNb-1a conjugated to
polyethylene glycol (PEG) was developed as a potential
treatment for relapsing–remitting MS (RRMS). This
pegylation process was designed to extend the half-life of
IFNb-1a and enable a less frequent dosing schedule. The
ongoing phase III ADVANCE study (see Table 5 for full
trial names) aims to determine the clinical efficacy of PEG-
IFNb-1a administered once every 2 weeks or every
4 weeks via SC injection in patients with relapsing MS
[40].
2.2 Glatiramer Acetate
2.2.1 Mechanism of Action and Immunological Effects
GA was first approved as a daily injectable treatment for
RRMS in 1996 and, like the IFNs, it is a frequently used
first-line agent [10, 11]. More recently, a higher dose
formulation (40 mg) administered three times per week
has been approved in the US for use in patients with
RRMS [41]. GA consists of a heterogeneous polypeptide
mixture made of glutamic acid, lysine, alanine, and
tyrosine that was designed to simulate myelin basic pro-
tein, one of the major myelin auto-antigens classically
used to induce experimental autoimmune encephalomy-
elitis (EAE) in animal models, and also thought to be
involved in MS.
The exact MoA of GA is not fully understood [42];
however, it appears to shift the GA-reactive lymphocyte
population from a pro-inflammatory T helper (Th) 1 state to
an anti-inflammatory Th2 state. In various studies, GA
has also been shown to increase levels/expression of
Table 4 Adverse events commonly associated with each disease-modifying therapy and occurring more frequently than placebo in placebo-
controlled studiesa
Therapy Most commonb adverse events
Interferonb-1a/b Flu-like symptoms, headaches, injection-site reactions, and elevated liver enzymes
Flu-like symptoms and depression were the most common causes of discontinuation
Glatiramer
acetate
Injection-site reactions, vasodilatation, rash, dyspnea, and chest pain (not of cardiac origin)
Injection-site reactions, dyspnea, urticaria, vasodilatation, and hypersensitivity were the most common causes of
discontinuation
Mitoxantrone Nausea, vomiting, alopecia, and urinary tract infections
Leucopenia, depression, decreased left-ventricular ejection fraction, bone pain, repeated urinary tract infections, and
hydronephrosis were the causes of discontinuation
Natalizumab Headache, fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression,
pain in extremity, abdominal discomfort, diarrhea, and rash
Urticaria and other hypersensitivity reactions were the most common causes of discontinuation
Fingolimod Headache, flu-like symptoms, diarrhea, back pain, liver enzyme elevations, cough, and bradycardia at treatment onset
Serum transaminase elevation was the most common cause of discontinuation
Teriflunomide Serum alanine aminotransferase increased, alopecia, diarrhea, flu-like symptoms, nausea, and paresthesia
Alopecia was the most common cause of discontinuation
Dimethyl
fumarate
Flushing, abdominal pain, diarrhea, and nausea
Gastrointestinal events, flushing, and elevated hepatic transaminases were the most common causes of discontinuation
Alemtuzumab Rash, headache, pyrexia, and respiratory tract infections
Immune thrombocytopenic purpura, thyroid disorders, nephropathies, cytopenias, infusion-associated reactions, and
infections were also associated with infusions
Laquinimod Headaches, nasopharyngitis, and back pain
Elevations in alanine transaminase were the most common cause of discontinuation
a Phase III studies involving daclizumab [165] and ocrelizumab [168] are ongoing, and adverse events commonly associated with these drugs are
not included in this table
b The reported common adverse events include those occurring at a frequency of[1/10 and C1/100, based on product labels where available, or
from pivotal publications for therapies yet to gain an indication
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anti-inflammatory IL-10 and IL-4 cells, and decrease levels
of proinflammatory TNF and IL-12 cells [23]. Daily usage
appears to selectively promote trans-endothelial migration
of Th2 cells across the BBB [43] and stimulate the release
of anti-inflammatory cytokines [44]. There is no informa-
tion regarding the absorption, distribution, metabolism, or
excretion profiles of GA in humans as there is currently no
direct and sensitive analytical method for measuring the
compound in biological fluids. Therefore, it is also not
known whether GA crosses the BBB.
A growing body of evidence suggests that GA leads to a
broader immunomodulatory effect on cells of both the
innate and adaptive immune system [23]. GA-mediated
modulation of antigen-presenting cells (APCs) such as
monocytes and dendritic cells, CD4? Th cells, CD8? T
cells, Forkhead box P3? regulatory T cells, natural killer
cells, and antibody production by plasma cells have been
reported [23]. In addition, most recent investigations indi-
cate that GA treatment may also promote regulatory B-cell
properties, with a reciprocal reduction in the expression of
proinflammatory cytokines [45, 46]. T-cell-induced brain-
derived neurotrophic factor (BDNF) secretion following
GA administration has also been described in MS, EAE,
and experimental cell lines [47]. However, the clinical
implications of this are not fully understood.
2.2.2 Clinical Effects in Relapsing MS
The efficacy of GA in reducing relapses in patients with
MS has been demonstrated in several randomized, con-
trolled clinical trials (Tables 2, 3) and post hoc analyses
[48]. The efficacy of GA on relapse reduction was similar
to that of IFN therapy in the BECOME, BEYOND, and
REGARD trials, with similar annualized relapse rates
(ARRs) [49–51]. Combined GA and IFN therapy did not
reduce the risk of relapse compared with GA therapy alone
over 3 years in the CombiRX trial [52]. The most common
adverse events associated with GA therapy are injection
site reactions, vasodilation, and rash (summarized in
Table 4). Following GA injection, an immediate systemic
reaction can occur in some patients, leading to chest
tightness, dyspnea, and bradycardia lasting up to 20 min-
utes, but this reaction is not considered to be life threat-
ening [53]. Rates of discontinuation were similar to those
Table 5 Acronyms and full trial names/study groups
Acronym Full trial name/study group
ADVANCE Efficacy and Safety Study of BIIB017
AFFIRM Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis
ALLEGRO Safety and Efficacy of Orally Administered Laquinimod for Treatment of Relapsing Remitting Multiple Sclerosis
BECOME Betaseron vs Copaxone in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints
BEYOND Betaferon Efficacy Yielding Outcomes of a New Dose in multiple sclerosis patients
BRAVO Benefit and Risk Assessment of Avonex and Laquinimod
CARE-MS Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis
CombiRX Combination Therapy in Patients With Relapsing–Remitting Multiple Sclerosis
CONFIRM Comparator and an Oral Fumarate in RRMS
DEFINE Efficacy and Safety of Oral BG00012 in Relapsing–Remitting Multiple Sclerosis
EVIDENCE Evidence of Interferon Dose-Response: European North American Comparative Efficacy
FREEDOMS FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis
INCOMIN Independent Comparison of Interferon
MIMS Mitoxantrone in Multiple Sclerosis
MSCRG Multiple Sclerosis Collaborative Research Group
MSSG Multiple Sclerosis Study Group
PRISMS Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis
REGARD Rebif vs Glatiramer Acetate in Relapsing MS Disease
TEMSO Teriflunomide Multiple Sclerosis Oral
TENERE Teriflunomide and Rebif
TOWER Teriflunomide Oral in People With Relapsing Remitting Multiple Sclerosis
TRANSFORMS Trial Assessing Injectable Interferon vs FTY720 Oral in RRMS
Immunological MoA and Clinical Profile of DMTs in MS 545
for IFN formulations in clinical studies [49–51]. No new
adverse events appeared in patients treated with a high-
dose formulation of GA administered three times per week
[41].
2.3 Mitoxantrone
2.3.1 Mechanism of Action and Immunological Effects
Mitoxantrone was approved in the US in 2000 for use in
‘‘patients with secondary progressive, progressive relapsing
or worsening relapsing–remitting multiple sclerosis’’ [54].
It is a synthetic anthracenedione traditionally used as an
anti-neoplastic agent. Mitoxantrone intercalates with the
DNA of both proliferating and non-proliferating cells
causing strand breaks, and also inhibits DNA repair via
inhibition of topoisomerase II [55]. It is thought that the
mechanism by which mitoxantrone exerts its therapeutic
effect in MS is through inhibition of proliferation of B and
T lymphocytes and macrophages [54]. Additionally, sev-
eral other immunosuppressive effects have been described,
such as decreased secretion of IFNc, TNFa, and IL-2 [56].
2.3.2 Clinical Effects in Relapsing MS
Mitoxantrone is administered by intravenous infusion
every 3 months at a dose that is body-weight dependent
(12 mg/m2). Table 2 summarizes data regarding clinical
efficacy on disease relapses and disability progression of
mitoxantrone from the randomized, placebo-controlled,
phase III MIMS trial [55]. Meta-analyses show that
mitoxantrone is associated with a significant effect on MS
relapses and disability progression compared with placebo
[57].
The most common adverse events are nausea, vomiting,
alopecia, and urinary tract infections, as summarized in
Table 4 [54]. Cardiotoxicity, neutropenia, amenorrhea,
which in some cases may be permanent, and the potential
for late-occurring leukemia are the major safety concerns
associated with mitoxantrone use [57].
2.4 Natalizumab
2.4.1 Mechanism of Action and Immunological Effects
Natalizumab is a recombinant humanized monoclonal
antibody produced in murine myeloma cells [17]. Natal-
izumab is a selective adhesion molecule inhibitor; it binds
specifically to a4-subunits of a4b1 and a4b7 integrins
expressed on the surface of all white blood cells (WBCs),
except neutrophils [58]. This inhibits a4-mediated adhe-
sion of WBCs to their counter-receptors, including vascular
cell adhesion molecule-1 (VCAM-1) [59], and reduces
very late antigen-4 expression on all investigated immune
cells, including B cells [60]. This produces a number of
phenotypic changes in the immune composition of
peripheral blood [61].
Natalizumab increases the percentage of activated leu-
kocytes producing pro-inflammatory cytokines, which has
been attributed to sequestration of activated lymphocytes in
the peripheral circulation [62, 63]. The CD4/CD8 ratio is
reduced with long-term therapy [64], and serum immuno-
globulin (Ig) M and IgG levels decrease significantly with
continued therapy [65]. Natalizumab also increases the
number of circulating CD34? hematopoietic progenitors
by interfering with homing to bone marrow [66]. In addi-
tion, increases in peripheral natural killer cells have been
observed with natalizumab treatment. This effect may play
a role in its efficacy, but further investigation is required
[23].
Through the disruption of various molecular interac-
tions, natalizumab is believed to directly inhibit transmi-
gration of leukocytes into the CNS and inflamed
parenchymal tissue [59], thus reducing the formation of
MS lesions. Treatment with natalizumab may also inhibit
the ongoing inflammation mediated by leukocytes already
present in the CNS by interrupting their interaction with the
extracellular matrix proteins [67]. One study has shown
that natalizumab can cross the BBB, although the full
implications of this finding are yet to be determined [68].
2.4.2 Clinical Effects in Relapsing MS
Natalizumab intravenous infusion was approved as a
treatment for RRMS in 2007, and is used mainly as a
second-line therapy [16, 17]. The phase III, placebo-con-
trolled AFFIRM study demonstrated the efficacy of natal-
izumab in reducing disease relapses and preventing
disability progression [69], and subsequent meta-analyses
confirmed these findings [70, 71]. At present, there are no
direct head-to-head comparisons of natalizumab with other
DMTs (Table 3), but the numerical differences in the
findings seen in AFFIRM suggest this agent may be more
effective than the IFNbs and GA in terms of reducing
relapses (Table 2).
In a prospective, observational cohort study of 73 MS
patients treated with natalizumab, development of anti-
bodies to the agent occurred by week 24 in 58 % of the
patients [72]. The majority of these patients reverted to an
anti-natalizumab-negative status at follow-up. However,
the persistence of anti-natalizumab antibodies in the
minority of patients correlated with a reduction in serum
natalizumab levels and decreased drug efficacy [72, 73].
The most common adverse events associated with na-
talizumab therapy are headache, fatigue, and respiratory
tract infections (summarized in Table 4). The immune
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system effects of natalizumab may increase the risk of
infections, including pneumonia, urinary tract infections,
gastroenteritis, vaginal infections, tooth infections, tonsil-
litis, and herpes infections [17, 69].
Most notably, long-term exposure to natalizumab
increases the risk of progressive multifocal leukoencepha-
lopathy (PML), an opportunistic infection caused by the
John Cunningham virus (JCV), which can reactivate in
patients who are immunocompromised [74]. As of Sep-
tember 2013, over 120,500 patients worldwide had
received natalizumab and, as of November 2013, there had
been 418 confirmed post-marketing cases of PML among
these individuals leading to 96 deaths (23 %) [75]. Risk
factors for development of PML in natalizumab-treated MS
patients include a positive anti-JCV antibody test, prior use
of immunosuppressants, and exceeding 24 months of na-
talizumab treatment [76]. Presence of all three factors
increases the risk of PML by about 20-fold compared with
having a positive anti-JCV antibody test alone, and by over
100-fold compared with a negative test for JCV antibodies
[77]. Given that anti-JCV antibodies are found in 50–60 %
of the general population, healthcare providers are advised
to stratify their patients to treatment according to anti-JCV
status and other risk factors. Additionally, it is recom-
mended that patients receiving natalizumab who test neg-
ative for anti-JCV antibodies should be retested every
6 months [76] as seroconversion rates are estimated to be
between 2.0 % and 14.5 % per year [78, 79]. Immune
reconstitution inflammatory syndrome after withdrawal of
natalizumab has been observed in at least 90 % of patients
with PML, leading to death in 29 % [17, 80, 81].
Due to the risk of infections following natalizumab
therapy, it is suggested that a washout period may be
required before switching from natalizumab to another
immunomodulatory therapy [82]. The pharmacodynamic
effects of natalizumab are reported to last for 12 weeks
according to the European Summary of Product Charac-
teristics, but some reports suggest that some effects may
continue for as long as 6 months [83]. However, this must
be balanced with the risk of severe relapse if treatment with
the new agent is delayed for too long [78, 84–88]. There-
fore, the optimal time to initiate a new therapy after na-
talizumab discontinuation requires further investigation,
and should also be considered on an individual patient
basis to maximize efficacy and reduce risk of disease
relapse and residual natalizumab effects.
2.5 Alemtuzumab
2.5.1 Mechanism of Action and Immunological Effects
Alemtuzumab is a recombinant, DNA-derived, humanized
monoclonal antibody that targets CD52, a cell surface
protein predominantly found in B and T lymphocytes [89].
Alemtuzumab is administered by intravenous infusion once
per year, and is currently approved for the treatment of
B-cell chronic lymphocytic leukemia and has recently been
approved in the EU as a therapy for RRMS [22]. Treatment
with alemtuzumab results in a rapid and long-lasting
depletion of lymphocyte populations, after which homeo-
static reconstitution leads to alterations in cell subsets,
causing long-lasting changes in adaptive immunity [90].
2.5.2 Clinical Effects in Relapsing MS
Results from two phase III trials involving alemtuzumab
are available (Table 3). Both trials compared the efficacy
of alemtuzumab against IFNb-1a in the treatment of
RRMS. Superiority of alemtuzumab over active compara-
tor in terms of relapse reduction, reduced inflammatory
lesion activity, and reduced rate of brain parenchymal
fraction reduction (a measure of brain atrophy) was
observed in both the CARE-MS I and CARE-MS II studies
[91, 92]. CARE-MS II also demonstrated improvement in
sustained disability progression versus IFNb-1a [92],
although a disability benefit according to the Expanded
Disability Status Scale compared with IFNb-1a was not
seen in the CARE-MS I trial [91].
The most common adverse events associated with ale-
mtuzumab were headache, diarrhea, and flu-like symptoms
(summarized in Table 4). Infections were more frequent
with alemtuzumab than with IFNb; notably cutaneous
herpes was more common despite prophylactic acyclovir.
The most common infections in patients receiving ale-
mtuzumab included upper respiratory and urinary tract
infections, sinusitis, and herpes simplex infections. Infec-
tions were predominantly mild to moderate in severity and
there were no treatment-related life-threatening or fatal
infections [91, 92].
Approximately 16–19 % of alemtuzumab-treated
patients developed an autoimmune thyroid-related adverse
event and approximately 1 % developed a serious thyroid-
related event. Approximately 1 % developed immune
thrombocytopenic purpura, and patient monitoring for
immune cytopenias and thyroid or renal disorders is
required for all clinical trials of alemtuzumab in MS
[91, 92].
Alemtuzumab treatment significantly depletes mononu-
clear and lymphocyte subsets. Studies have shown that
CD4 cells are depleted for up to 5 years and CD8 cells for
2.5 years. Monocytes and B cells return to baseline levels
within 3 months of stopping treatment [90, 93]. Presum-
ably, the capacity for immune-cell reconstitution is age
dependent, as it is well documented that thymic production
of new T cells declines as part of the normal ageing process
[94, 95], although appropriate studies have not been
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performed on patients older than 55 years [22]. Regardless,
as a result of its prolonged effects on WBCs, it is likely that
a washout period of several months, at least, may be
required following cessation of alemtuzumab therapy,
before starting another immunosuppressant treatment.
3 Orally Administered Therapies
3.1 Fingolimod
3.1.1 Mechanism of Action and Immunological Effects
Fingolimod is an orally administered, sphingosine
1-phosphate (S1P) receptor modulator used to treat
relapsing forms of MS. It is a chemical derivative of
myriocin, a metabolite of the fungus Isaria sinclairii,
known for its anti-inflammatory properties [96].
Fingolimod reversibly redistributes lymphocytes into
lymphoid tissue, whilst preserving lymphocyte function
[97, 98]. By inducing internalization of S1P receptors
(S1PRs) expressed on lymphocytes [99], fingolimod pri-
marily inhibits egress of naı¨ve and central memory lym-
phocytes from lymph nodes back into the circulation [100–
102] and thereby prevents them from circulating to other
tissues, including the CNS [98, 101]. However, effector
memory lymphocytes, which are less dependent on S1P
signaling for egress and do not regularly recirculate
between lymphoid tissues, are less affected by fingolimod
[101, 102]. These cells are mainly located in peripheral
tissues and play a key role in preserving immunosurveil-
lance [102].
Animal studies suggest that fingolimod does not impair
the ability of lymphocytes (including the lymphocytes that
are retained in the lymph nodes) to become activated,
proliferate, and produce cytokines or antibodies [100]. The
evidence suggests further that fingolimod does not inhibit
humoral immunity to systemic viral infection, and does not
suppress, or only modestly suppresses, the generation of
virus-specific cytotoxic T cells in lymph nodes [102, 103].
Additionally, it has been demonstrated that fingolimod-
treated individuals can mount vaccine-specific adaptive
immune responses comparable to those of healthy controls
[104, 105].
As well as its immunomodulatory effects, fingolimod
may have a direct effect on the CNS as it can readily cross
the BBB [18]. S1PRs are widely expressed on CNS-resi-
dent cells and have been reported to regulate several pro-
cesses relevant to MS pathology. In animal models of
encephalomyelitis, fingolimod, acting via S1PRs, reduced
disease severity, restored motor function, and preserved
brain tissue [106]. In a variety of different preclinical
neurodegenerative models, fingolimod has been found to
reduce astrogliosis, demyelination, and axonal loss [99,
101, 107], and protect from exocytotoxic insults, as well as
potentially supporting neuroregenerative processes by
enhancing recovery of myelin [108], restoring the function
of neural cells [109], and increasing levels of neurotrophic
factors, such as BDNF [110]. In addition, there is also
preclinical evidence indicating that these effects may be
independent of reductions in peripheral lymphocyte counts
[107]. Recent evidence suggests S1P biology is altered in
the CSF and on reactive astrocytes in white and grey matter
lesions of MS patients [111–113].
3.1.2 Clinical Effects in Relapsing MS
In 2010, fingolimod became the first oral drug to be approved
for the treatment of relapsing forms of MS [18, 19]. Fingoli-
mod reduced relapses by 54 %, and delayed disability pro-
gression, lesion activity, and brain volume loss versus placebo
over 2 years in the pivotal, randomized FREEDOMS clinical
trial (Table 2) [114]. In a head-to-head phase III study of oral
daily fingolimod versus IFNb-1a IM in patients with MS
(TRANSFORMS; Table 3), there were significantly greater
reductions in relapse rate (52 % relative reduction), lesion
activity, and brain volume loss with fingolimod than with
IFNb after 1 year [115]. In addition, meta-analyses indicate
that fingolimod is more efficacious in reducing relapses than
all IFNb formulations and GA [116, 117]. The MoA of fin-
golimod likely accounts for its significant efficacy profile. The
ability of fingolimod to readily cross the BBB, and potentially
have direct effects within the CNS, may account, at least in
part, for the consistently significant reductions (occurring
within 6 months) in the progression of brain atrophy observed
during all phase III pivotal trials.
The most common adverse events associated with fingo-
limod therapy are headache, flu-like symptoms, and diarrhea
(summarized in Table 4). Fingolimod is generally well tol-
erated and discontinuation rates due to adverse events and
severe adverse events were similar to discontinuation rates in
placebo groups [114]. Two fatal herpetic infections occurred
in TRANSFORMS in patients who received fingolimod at a
higher-than-approved dose of 1.25 mg: one case each of
herpes simplex virus encephalitis and disseminated primary
varicella infection. The latter occurred in a patient without
previous exposure to varicella who was also receiving high-
dose corticosteroids for an MS relapse at the time of exposure
to primary infection [115]. These cases are reported on a
background of more than 71,000 patients treated with fin-
golimod in both the post-marketing and clinical-trial settings
[118], and in a pooled population of patients from two phase
III and one phase II studies and their extensions; serious
infections were reported in 2.1 % of patients [119].
A core pharmacodynamic effect of fingolimod is a
reversible reduction of the peripheral lymphocyte count to
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approximately 30 % of baseline values [19]. The reversible
reduction in lymphocyte counts occurs without an overall
increase in infections relative to placebo, suggesting that
during fingolimod therapy, peripheral lymphocyte counts
do not reflect immunocompetence [119]. The lymphocyte
count recovers back to normal levels within 1–2 months
after fingolimod treatment discontinuation, and a 6-week
washout period is recommended [19].
Another expected and well characterized pharmacody-
namic effect is observed at treatment initiation. This first-
dose effect presents as a transient, mostly asymptomatic,
and self-limiting decrease in heart rate. The transient nature
of heart rate effects is explained by the initial functional
agonism and subsequent rapid internalization of S1PRs on
atrial myocytes [120]. Bradycardia was typically asymp-
tomatic, observed within 6 hours of the first dose, and
resolved with continued treatment. Hence, the EU label
recommends a 6-hour monitoring period after the first dose
and an electrocardiogram prior to treatment initiation [19].
Fingolimod is contraindicated in patients with certain pre-
existing heart conditions, stroke, or who are taking certain
anti-arrhythmic medications.
Other known adverse effects reported in association
with the MoA of fingolimod are generally infrequent and
have a known temporal profile, which allows for appro-
priate monitoring. This includes macular edema occurring
in approximately 0.4 % of patients receiving fingolimod
0.5 mg and presenting within 3–4 months of treatment
initiation (patients with a history of uveitis appear to have
an increased risk), which generally resolved with or with-
out treatment after drug discontinuation [121], and
reversible elevation of liver enzymes, mainly occurring in
the first 6–12 months of treatment [19].
3.2 Teriflunomide
3.2.1 Mechanism of Action and Immunological Effects
Teriflunomide is an active metabolite of leflunomide, an
approved oral therapy for rheumatoid arthritis since 1998
[122]. In 2012, oral teriflunomide was approved for treatment
of relapsing forms of MS [20]. The exact mechanism by which
teriflunomide exerts its therapeutic effect in MS is not com-
pletely understood [123]. It is believed that the drug works by
inhibiting dihydroorotate dehydrogenase (DHODH), a mito-
chondrial enzyme involved in de novo pyrimidine synthesis.
By inhibiting DHODH and reducing DNA synthesis, teri-
flunomide has a cytostatic effect on proliferating T and B cells
[124]. However, cellular salvage pathways for proliferation
exist and allow slowly dividing T memory cells to sustain
ongoing pyrimidine metabolism and to survive [125]. Teri-
flunomide was shown to interfere with the interaction of T cells
and APCs, which is central to the immune response [126].
There is also evidence that teriflunomide blocks TNFa-
induced activation of nuclear factor kappa B (NF-jB)
[127], inhibits adhesion molecules and matrix metallopro-
teinases [128], and disrupts the interaction between T cells
and APCs and integrin signaling during T-cell activation
[129]. In vitro studies using Jurkat and cytotoxic T-lym-
phocyte line-4 cells have demonstrated the inhibition of
tyrosine kinase pathways following teriflunomide admin-
istration [130]. Animal experiments with leflunomide have
shown that some immunosuppressive effects can be
reversed by uridine as a substitute for inhibited DHODH-
dependent pyrimidine synthesis, whereas others cannot,
thus attesting to the in vivo relevance of the compound’s
interference with immune cell signaling [131].
3.2.2 Clinical Effects in Relapsing MS
Teriflunomide has been associated with significant efficacy
(in terms of reducing relapses by approximately 30 % and
delaying disability progression [14-mg dose only]) versus
placebo in the pivotal, randomized TEMSO [132] and
TOWER [133] clinical trials (Table 2). In addition, a head-
to-head study has been conducted showing no superiority
of oral daily teriflunomide versus IFNb-1a SC in patients
with MS (TENERE; Table 3).
The most common adverse events with teriflunomide are
alopecia, diarrhea, and flu-like symptoms (summarized in
Table 4). The increase in liver enzyme levels is of interest.
As stated, teriflunomide is the active metabolite of lefluno-
mide. Liver toxicity is one of the most serious safety con-
cerns associated with leflunomide. In rare cases, leflunomide
has been associated with severe hepatic injury leading to
death in patients with rheumatoid arthritis. As a conse-
quence, MS care providers should monitor liver function
prior to and during treatment with teriflunomide [134].
A mean decrease in lymphocyte count of approximately
15 % and in platelet count of approximately 10 % was
observed, but no overall increase in the risk of serious
infections was reported in clinical trials with teriflunomide
[132]. Fatal infections have been reported in the post-
marketing setting in patients receiving leflunomide [134].
Teriflunomide is teratogenic in animal models and so
women of childbearing potential must present a negative
pregnancy test before starting the drug and use effective
birth control during treatment [134].
Teriflunomide is eliminated slowly from plasma. With-
out an accelerated elimination procedure, it takes
an average of 8 months to reach plasma concentra-
tions \0.02 mg/L, although because of individual varia-
tions in drug clearance it may take as long as 2 years [134].
An accelerated elimination procedure could be used at any
time after discontinuation of teriflunomide. Elimination
can be accelerated by using either cholestyramine or oral
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activated charcoal powder for 11 days [134]. At the end of
11 days, both regimens successfully accelerated terifluno-
mide elimination, leading to a more than 98 % decrease in
teriflunomide plasma concentrations.
3.3 Dimethyl Fumarate (BG-12)
3.3.1 Mechanism of Action and Immunological Effects
Dimethyl fumarate (DMF) is a methyl ester of fumaric
acid. Early reports identified it as a potent cell radio-sen-
sitizer. The large enhancement of radiation sensitivity was
due to thiol depletion, thought to be responsible for radio
resistance [135]. Fumaric acid esters have also been used
successfully as psoriasis therapy since 1959 and are
thought to have therapeutic potential for other dermato-
logical and non-dermatological conditions [136].
The MoA by which DMF exerts its therapeutic effect in
MS is not fully understood [137]. It has been proposed that
fumarates may promote cytoprotection via the nuclear
factor (erythroid-derived 2)-like 2 (Nrf2) transcription
pathway [138]. DMF is rapidly metabolized to the
metabolite, monomethyl fumarate (MMF). Both DMF and
MMF have short half-lives, so DMF requires twice-daily
administration [137]. DMF and MMF have been shown to
activate the Nrf2 pathway in vitro and in vivo in animals
and humans [137], with a corresponding increase in cel-
lular redox potential, glutathione levels, adenosine tri-
phosphate levels, mitochondrial membrane potential, and
other anti-oxidative effects resulting in cytoprotective
effects [138, 139]. It is worth noting that activation of the
Nrf2 pathway has been implicated in tumorigenesis [140],
although the clinical relevance of this in MS is unclear.
Other reported immunosuppressive effects of DMF
include induction of the anti-inflammatory heme oxygen-
ase protein via glutathione depletion [141], inhibition of
cytokine-induced nuclear translocation of NF-jB apoptosis
of stimulated T cells [142], and modulation of B-cell
apoptosis and upregulation of monocyte superoxide anion
production [143]. In vitro studies have indicated the role of
DMF in promoting the Th2-associated cytokines IL-4 and
IL-5 in stimulated T cells, while down-regulating Th1
responses and inhibiting expression of intracellular adhe-
sion molecule-1, E-selectin, and VCAM-1 [144]. Addi-
tionally, DMF has been identified as a nicotinic acid
receptor agonist in vitro [137], which may be linked to the
flushing events observed in MS patients (Table 2) [145].
3.3.2 Clinical Effects in Relapsing MS
DMF was approved in 2013 for treatment of relapsing
forms of MS [21, 146]. DMF has shown significant efficacy
(in terms of reducing relapses by 53 %, delaying disability
progression, and reducing the number of gadolinium-
enhancing and new or enlarging T2-weighted hyperintense
lesions) versus placebo in the DEFINE trial (Table 2)
[147]. In another 2-year, phase III study with GA as a
reference comparator (CONFIRM), DMF reduced inflam-
matory disease activity and did not significantly reduce
disability progression [148].
The most common adverse events associated with DMF
therapy are flushing, abdominal pain, and diarrhea (sum-
marized in Table 4). The incidence of gastrointestinal events
was higher early in the course of treatment (primarily in
month 1) and usually decreased over time in patients treated
with DMF versus placebo. A total of 5 and 6 % of patients in
twice-daily and thrice-daily groups, respectively, discon-
tinued DMF due to gastrointestinal events in DEFINE [147].
DMF has also been associated with elevation of hepatic
transaminases (mostly\3 times the upper limit of normal)
and transient increase in mean eosinophil counts was seen
during the first 2 months of therapy [137].
In CONFIRM and DEFINE, mean lymphocyte counts
decreased by approximately 30 % during the first year of
treatment with DMF and then remained stable [137, 147,
148]. Guidance on a washout period between stopping DMF
therapy and starting another MS therapy is not currently
available. According to the US label, mean lymphocyte
counts increased, but did not return to baseline, 4 weeks after
stopping DMF [137]. The incidence of infections and serious
infections was reported to be comparable to that with pla-
cebo; however, there have been a total of four reports of PML
and one report of Kaposi’s sarcoma [149] in patients with
psoriasis who were treated with fumarates (treatment with a
mixture of DMF and the calcium, magnesium, and zinc salts
of ethylhydrogen fumarate with the registered trade name of
Fumaderm) in the context of 180,000 patient-years of
Fumaderm treatment [149–151]. To date, there have been
no reports of PML or Kaposi’s sarcoma among patients with
MS treated with DMF [147, 148].
4 Therapies in Late-Stage Development
4.1 Laquinimod
4.1.1 Mechanism of Action and Immunological Effects
Laquinimod is a synthetic, experimental compound being
investigated as an oral treatment for MS. Laquinimod is a
successor to the discontinued experimental drug linomide
[152]. Linomide was tested in phase III trials, but clinical
development was terminated due to severe cardiovascular
toxicity [152]. Chemical modification of the linomide
structure has given laquinimod a favorable toxicological
profile and improved potency in EAE animal models [153].
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Laquinimod is thought to work by shifting the CD4?
phenotype from the proinflammatory Th1 pattern in favor
of the Th2/Th3 pattern (increased IL-4 and IL-10 produc-
tion) and inhibiting the infiltration of inflammatory cells
into the CNS [23, 154]. Several groups have also shown
that laquinimod reduces leukocyte migration into the CNS
[153, 155]. Another potential MoA is the suppression of
major histocompatibility complex class II antigen presen-
tation and down-regulation of epitope spreading [156].
As well as these immunomodulatory effects, it has been
postulated that laquinimod may confer a degree of neuro-
protection. Treatment with laquinimod is associated with
significantly higher levels of BDNF in the CNS [23]. In
animal models, laquinimod crossed the BBB. In doing so,
laquinimod might exert direct effects within the CNS,
although it is not yet clear how this may occur, or indeed
whether this has any relevance in a clinical setting [157].
4.1.2 Clinical Effects in Relapsing MS
In a phase III, randomized, placebo-controlled study in
patients with RRMS (ALLEGRO), treatment with laquini-
mod led to a modest but significant reduction in the mean
ARR, a significant reduction in disability progression, and a
significantly reduced number of both gadolinium-enhancing
and new or enlarging T2-weighted lesions compared with
placebo (Table 2) [158]. In a second phase III, randomized,
placebo- and IFNb-1a IM-controlled study in patients with
RRMS (BRAVO), laquinimod significantly reduced pro-
gression of disability and brain atrophy. In this study, laqu-
inimod failed to reduce the ARR versus placebo in the
primary analysis (Table 3). However, when the data were
adjusted for baseline clinical factors associated with relapse
rate that were imbalanced between treatment groups, the
ARR in the placebo group increased to lead to a statistically
significant advantage for laquinimod over placebo [159].
The most common adverse events associated with laqu-
inimod therapy are headache, nasopharyngitis, and back pain
(summarized in Table 4). In clinical trials, back pain, cough,
headache, and depression appeared to occur more frequently
with laquinimod than with placebo [158, 159]. In the phase III
studies, most adverse events were similar to placebo in fre-
quency [158, 159], although transient elevations of alanine
aminotransferase C3 times the normal level were seen more
frequently with laquinimod than placebo and IFNb [158, 159].
4.2 Daclizumab
4.2.1 Mechanism of Action and Immunological Effects
Daclizumab is a humanized monoclonal antibody which
binds to the a-subunit (CD25) of the IL-2 receptor
expressed on activated T cells and CD4?CD25?FoxP3?
regulatory T cells [160]. This results in the inhibition of
several IL-2-dependent T-cell functions, including antigen-
and mitogen-induced proliferation, cytokine secretion by
activated Th1 and Th2 lymphocytes, and interference with
CD28-dependent CD40 ligand expression [161]. It has also
been proposed that daclizumab results in expansion and
activation of immunoregulatory CD56bright natural-killer
cells, which are able to gain access to the CNS and sup-
press activation of pathogenic immune responses [162].
4.2.2 Clinical Effects in Relapsing MS
Daclizumab is administered by subcutaneous injection
every 4 weeks. Phase II clinical trials showed that dac-
lizumab, as add-on or monotherapy in RRMS, had a dose-
dependent effect on reducing relapse rate, disability pro-
gression, and the number and volume of gadolinium-
enhancing T1 and T2 lesions over 12 months [163, 164].
Adverse events were equally distributed across treatment
groups; however, serious adverse events attributed to dac-
lizumab treatment emerged. These were categorized into
four main groups: infections, skin reactions, liver abnor-
malities, and autoimmune phenomena [160]. Phase III
clinical trials in patients with RRMS are ongoing [165].
4.3 Ocrelizumab
4.3.1 Mechanism of Action and Immunological Effects
Ocrelizumab is a humanized, recombinant monoclonal
antibody reactive against CD20, which is widely expressed
on B cells [166]. It is administered as an intravenous infusion
on days 1 and 15 at approximately 6-month intervals [167].
Treatment with ocrelizumab results in B-cell depletion
[167], but the precise role of this activity in MS is not known.
4.3.2 Clinical Effects in Relapsing MS
A phase II clinical trial showed that ocrelizumab had a
dose-dependent effect on reducing the number of gado-
linium-enhancing T1 lesions over 24 weeks compared with
placebo in patients with RRMS [167]. A similar proportion
of patients had adverse events across treatment groups,
although a higher proportion of patients receiving ocre-
lizumab had infusion-related adverse events than in the
placebo group [167]. Phase III clinical trials in patients
with RRMS are ongoing [168].
5 Discussion
Several injectable, and now oral, DMTs are currently
available, or in late-stage clinical development, for the
Immunological MoA and Clinical Profile of DMTs in MS 551
treatment of relapsing forms of MS. All of the therapies
described in this review are believed to suppress autore-
active peripheral lymphocyte activity in CNS compart-
ments, which remains a critical step in the process of
demyelination and tissue damage in MS. Yet each therapy
has its own MoA and, as a consequence, each has a dif-
ferent efficacy and safety profile. In some cases, the exact
pharmacological mechanisms accounting for the thera-
peutic effects of an MS treatment remain unknown. For
example, studies on IFN, GA, DMF, and laquinimod have
demonstrated widespread effects within the immune sys-
tem. Other therapies, such as natalizumab, fingolimod,
teriflunomide, and alemtuzumab seem to exert a more
direct effect on lymphocytes. Additionally, some therapies
might have neuroprotective effects, although via differing
mechanisms and with different levels of supporting evi-
dence [23, 110, 169].
All the DMTs described here are able to reduce the risk
of inflammatory disease activity, as assessed by relapse rate
and magnetic resonance (MRI) lesion activity, compared
with placebo. However, few comparative head-to-head
trials have been undertaken to assess the superiority or non-
inferiority of one therapy against another, and there is a
need for such evidence now that numerous treatments for
MS are available. Those trials that have been undertaken
indicate that alemtuzumab and fingolimod provide greater
efficacy than IFNb [92, 115].
The ability of DMTs to reduce markers of disease
activity early in the disease course is an important long-
term efficacy consideration because the presence of these
markers, such as MRI lesion burden and clinical parame-
ters, correlate with severe disability in the long term [170–
172]. Early identification of probable treatment response
using these markers enables patients with a poor response
to be switched to an alternative therapy at an early stage
[170–172]. Additionally, brain atrophy has been shown to
correlate with long-term disease progression [173]. In this
regard, fingolimod is the only MS DMT to have demon-
strated consistently reduced brain-volume loss (a measure
of atrophy) across all of its phase III trials compared with
placebo and IFNb [114, 115].
Finally, the route of drug administration is usually a
significant determinant of a patient’s therapy preference.
IFNb-1a and 1b and GA are administered by SC or IM
injections; natalizumab and alemtuzumab are administered
by intravenous infusion; fingolimod, teriflunomide, and
laquinimod are administered orally once daily; and DMF
twice daily. As such, deciding on an MS treatment pathway
to match patients’ needs may also require physicians to
evaluate the potential for a particular treatment regimen to
affect patients’ long-term adherence to therapy, which in
turn directly affects clinical outcomes, such as relapse rate
[174].
6 Conclusions
Understanding the immunological mechanisms and associ-
ated clinical profiles of each therapy for MS is important, as
treatment tailored to provide optimal efficacy for patients
and potential adverse events can be readily identified and
managed appropriately. In light of our evolving knowledge
of the immunological mechanisms of some of the newer
therapies for MS, there appears to be a need for the devel-
opment of treatment algorithms to help physicians decide on
the most effective treatment pathway from the earliest stage
of MS, so that patients can benefit from high efficacy, high
tolerability treatments throughout the course of their disease.
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